Osiris Therapeutics (OSIR) Stock Price, News & Analysis

Company Overview

Osiris Therapeutics (OTCMKTS:OSIR) is a biotechnology company specializing in regenerative medicine and bioactive tissue products. The company focuses on harnessing the properties of human placental membranes and mesenchymal stem cells to support healing in a variety of clinical settings. Through its BioSurgery business unit, Osiris develops, manufactures and markets advanced wound care and surgical products designed to address unmet medical needs in wound management, orthopedic repair and soft tissue reconstruction.

Central to Osiris’s product portfolio is the Grafix® family of placental membrane products, which are cleared by the U.S. Food and Drug Administration for use in chronic, acute and surgical wounds. These products leverage naturally occurring growth factors, cytokines and extracellular matrix components to support the body’s own regenerative processes. In addition, the company’s Stravix™ and Bio4™ offerings provide bioactive tissue solutions for obstetric, orthopedic and soft tissue applications, enabling physicians to enhance healing outcomes and reduce the risk of complications.

Founded in 1992 by researchers at the University of Minnesota, Osiris Therapeutics has been at the forefront of mesenchymal stem cell research and development. The company was among the first to isolate and characterize adult stem cells capable of modulating inflammation and promoting tissue regeneration. Over the years, Osiris has forged strategic collaborations and licensing agreements with leading medical device and pharmaceutical companies, including Smith & Nephew and Stryker, to extend the reach of its proprietary technologies to global markets.

Headquartered in Columbia, Maryland, Osiris operates a state-of-the-art manufacturing facility compliant with Good Tissue Practices and ISO standards. The company’s products are distributed in the United States, Europe, Canada, Australia and select emerging markets. Under the leadership of CEO Peter Friedli, Osiris continues to expand its BioSurgery business while exploring new regenerative medicine applications through research partnerships and clinical studies.

Key Stats

• Today's Range: $18.99 to $18.99
• 50-Day Range: $18.99 to $18.99
• 52-Week Range: $7.01 to $19.30
• Volume: N/A
• Average Volume: 205,753 shs
• Market Capitalization: $655.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OSIR Stock Analysis - Frequently Asked Questions

How have OSIR shares performed this year?

Osiris Therapeutics' stock was trading at $18.99 at the start of the year. Since then, OSIR shares have increased by 0.0% and is now trading at $18.99.

How do I buy shares of Osiris Therapeutics?

Shares of OSIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Osiris Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Osiris Therapeutics investors own include Sierra Wireless (SWIR), MiMedx Group (MDXG), Achillion Pharmaceuticals (ACHN), Mallinckrodt (MNK), Bristol Myers Squibb (BMY), Ionis Pharmaceuticals (IONS) and Mesoblast (MESO).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:OSIR
• Previous Symbol: NASDAQ:OSIR
• CIK: 1360886
• Web: www.osiristx.com
• Phone: 443-545-1800
• Fax: N/A
• Employees: 342
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 34,528,000
• Free Float: N/A
• Market Cap: $655.69 million
• Optionable: Not Optionable
• Beta: N/A